小肠细菌过度生长与肠易激综合征  

Small intestinal bacteria overgrowth and irritable bowel syndrome

作　　者：陈坚[1] 邱志兵[1] 张会禄[1] 汤子慧 杨冬琴[1] CHEN Jian;Qiu Zhibing;Zhang Huilu;Tang Zihui;Yang Dongqin(Department of Digestive Disease,Huashan Hospital,Fudan University,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院消化内科

出　　处：《上海医药》2019年第15期7-10,共4页Shanghai Medical & Pharmaceutical Journal

摘　　要：本文概要介绍小肠细菌过度生长(small intestinal bacterial overgrowth,SIBO)和低度炎症在肠易激综合征患者中的发生率、SIBO的致病作用、利福昔明治疗伴有SIBO的肠易激综合征患者的疗效以及对利福昔明治疗失败的患者的补救治疗方法。The incidence and pathogenesis of small intestinal bacterial overgrowth(SIBO)and low-grade inflammatory response in irritable bowel syndrome(IBS)patients are introduced.The effects of rifaximin on IBS patients with SIBO and the remedial treatment for rifaximin-resistant IBS patients are also discussed.

关 键 词：肠易激综合征 小肠细菌过度生长 乳果糖呼气试验 低度炎症 利福昔明 

分 类 号：R574.4[医药卫生—消化系统] R363.21[医药卫生—内科学]